Cargando…
Prospective, monocentric, observational study of the long-term effectiveness of omalizumab in chronic urticaria
Omalizumab, a monoclonal antibody targeting IgE, has been approved in 2014 for the treatment of H1 antihistamine-refractory chronic urticaria. Data on long-term effectiveness and predictive factors for treatment response are currently limited. In this monocentric, prospective, observational study, 1...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dustri-Verlag Dr. Karl Feistle
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835204/ https://www.ncbi.nlm.nih.gov/pubmed/36644013 http://dx.doi.org/10.5414/ALX02376E |